Assay News and Research

RSS

Rapid point-of-care testing using screen-printed electrodes from Metrohm DropSens

Point-of-care testing with screen-printed electrodes allows rapid testing of populations for viral outbreaks – at affordable costs, without the need for trained specialists and/or complicated equipment.

From Metrohm USA Inc. 11 Jun 2020

Scientists investigate immune responses to SARS-CoV-2 spike immunogens

The coronavirus pandemic is actively spreading across the globe, with millions of people infected. Amid the global health crisis, scientists race to develop an effective vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

10 Jun 2020

Seroprevalence of IgM and IgG against SARS-CoV-2 in China

A new study published in the journal Nature Medicine in June 2020 reports the seroprevalence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) across China. This may help to understand the actual prevalence of the virus in the current pandemic.

10 Jun 2020

QuantuMDx receives CE-IVD marking for SARS-CoV-2 detection assay

QuantuMDx Group Limited, a UK-based life sciences company developing transformational point-of-care molecular diagnostics, today announces its SARS-CoV-2 detection assay has been CE-IVD marked under the In Vitro Diagnostics Directive (98/79/EC), enabling use within the European Union.

10 Jun 2020

Research demonstrates novel pathway regulating the underlying mechanism of NASH

CN Bio, a leading cell culture company that has developed single and multi-organ microphysiological systems that improve the accuracy and efficiency of drug discovery, today announced the publication of co-authored research led by researchers at the University of Cambridge in Nature Metabolism, identifying a novel pathway that regulates the underlying mechanism of Non-Alcoholic Steatohepatitis, potentially a new therapeutic target.

10 Jun 2020

G42 and Oxford Nanopore co-develop population-scale technology to detect SARS-CoV-2

Group 42 (G42), a leading AI and Cloud Computing company based in the United Arab Emirates, and Oxford Nanopore Technologies, an advanced sequencing technology company based in the United Kingdom, announced today they have developed an unprecedented population-scale technology that rapidly and accurately detects SARS-CoV-2, the virus that causes COVID-19.

10 Jun 2020

Coronavirus (COVID-19) sample tracking packages

To assist labs involved with the essential RT-PCR assay part of the “test, trace and isolate” strategy for dealing with the SARS-CoV-2 virus pandemic – Ziath has introduced two optimized packages for reliable tracking of patient samples submitted for Coronavirus (COVID-19) testing.

From Ziath Ltd 10 Jun 2020

Deep UV LED inactivation of SARS-CoV-2 - fast and effective

The ongoing pandemic has aroused considerable effort to find methods to prevent and control the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19 disease. Rapid inactivation devices would be of great help in this area, to prevent viral transmission through aerosols and contact with infected surfaces.

9 Jun 2020

Avacta provides update on COVID-19 antigen diagnostic test development with Adeptrix

Avacta Group plc is pleased to announce that a BAMS™ diagnostic test for COVID-19, being developed with Adeptrix, has reached the prototype stage.

From Avacta Life Sciences Ltd. 9 Jun 2020

Anti-RBD antibodies shown to neutralize active SARS-CoV-2

A new study published on the preprint server bioRxiv* in June 2020 reports the discovery of multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in samples from healthy donors, collected before the pandemic. These antibodies are capable of inhibiting the binding of the spike protein of the virus to the angiotensin-converting enzyme 2 (ACE2) molecule and can neutralize active infection of cells in culture.

9 Jun 2020

Synthetic monoclonal antibodies effectively neutralize SARS-CoV-2 in laboratory conditions

In a new study available on the preprint server bioRxiv*, a multinational research group demonstrated how monoclonal antibodies strongly inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro at even sub-nanomolar concentrations. This makes them a prime candidate for the treatment of coronavirus disease (COVID-19).

8 Jun 2020

Improving detection of SARS-CoV-2 infection among severely ill children

Researchers in the UK have conducted a study showing that children with a severe inflammatory syndrome had high levels of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), despite having tested negative for the virus by polymerase chain reaction (PCR).

8 Jun 2020

New EUbOPEN consortium will enable access to research tools to unlock disease biology

Frankfurt and Ingelheim. Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete.

8 Jun 2020

Zinc-finger antiviral protein makes SARS-CoV-2 highly susceptible to interferons

By looking into zinc-finger antiviral proteins (ZAP), a new study from Germany and the United Kingdom (UK) and available on the preprint server bioRxiv suggests that zoonotic transmission of a coronavirus with a specific genetic make-up facilitated the pandemic spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but also its sensitivity to interferons.

7 Jun 2020

Volcanic glass spray effective in controlling mosquitoes

An indoor residual spray made by combining a type of volcanic glass with water showed effective control of mosquitoes that carry malaria, according to a new study.

5 Jun 2020

A SARS-CoV-2 antibody magnetic immuno-detection test

A new report, released on the preprint server bioRxiv by researchers at the Fraunhofer Institute for Molecular Biology and Applied Ecology, describes the development of an innovative serologic test that could provide a fast, easy, and inexpensive method of detecting high titers of antibody in the serum of SARS-CoV-2 infected people.

4 Jun 2020

Universal preoperative screening of pediatric patients for COVID-19 improves safety

Universally screening pediatric patients for COVID-19 before they undergo surgical procedures has allowed hospitals to improve safety by identifying all patients who test positive for the virus, half of whom have no symptoms, according to new research led by Children's Hospital of Philadelphia

4 Jun 2020

Beckman Coulter Life Sciences’ RNAdvance Viral XP kit listed for use in EUA-authorized COVID-19 testing

Beckman Coulter Life Sciences today announced RNAdvance Viral XP has been added to the list of acceptable extraction methods for use in the Centers for Disease Control’s EUA-authorized COVID-19 test referenced in the FDA’s FAQ on testing for SARS-CoV-2. Laboratories are now permitted to independently validate RNAdvance Viral XP for use.

From Beckman Coulter Life Sciences 4 Jun 2020

New test identifies CAD-affected children who may benefit from uridine

Scientists at Sanford Burnham Prebys Medical Discovery Institute and the Centro de Biología Molecular Severo Ochoa in Spain have created a test that determines which children with CAD deficiency-; a rare metabolic disease-; are likely to benefit from receiving uridine, a nutritional supplement that has dramatically improved the lives of other children with the condition.

3 Jun 2020

New detection platform may help speed up viral diagnosis

The prompt, precise, and massive detection of a virus is the key to combat infectious diseases such as Covid-19.

3 Jun 2020

Assay News and Research

Rapid point-of-care testing using screen-printed electrodes from Metrohm DropSens

Scientists investigate immune responses to SARS-CoV-2 spike immunogens

Seroprevalence of IgM and IgG against SARS-CoV-2 in China

QuantuMDx receives CE-IVD marking for SARS-CoV-2 detection assay

Research demonstrates novel pathway regulating the underlying mechanism of NASH

G42 and Oxford Nanopore co-develop population-scale technology to detect SARS-CoV-2

Coronavirus (COVID-19) sample tracking packages

Deep UV LED inactivation of SARS-CoV-2 - fast and effective

Avacta provides update on COVID-19 antigen diagnostic test development with Adeptrix

Anti-RBD antibodies shown to neutralize active SARS-CoV-2

Synthetic monoclonal antibodies effectively neutralize SARS-CoV-2 in laboratory conditions

Improving detection of SARS-CoV-2 infection among severely ill children

New EUbOPEN consortium will enable access to research tools to unlock disease biology

Zinc-finger antiviral protein makes SARS-CoV-2 highly susceptible to interferons

Volcanic glass spray effective in controlling mosquitoes

A SARS-CoV-2 antibody magnetic immuno-detection test

Universal preoperative screening of pediatric patients for COVID-19 improves safety

Beckman Coulter Life Sciences’ RNAdvance Viral XP kit listed for use in EUA-authorized COVID-19 testing

New test identifies CAD-affected children who may benefit from uridine

New detection platform may help speed up viral diagnosis

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News